Garcia J, et al. - As a tool to identify the p.T790M epidermal growth factor receptor (EGFR) mutation in cell-free plasma DNA of non-small cell lung cancer patients, a BEAMing (beads, emulsion, amplification, and magnetics) assay (OncoBEAM-EGFR [Sysmex Inostics]) was compared to a next-generation sequencing assay (NGS; 56G Oncology panel kit, Swift Bioscience) in terms of performance. According to the findings, OncoBEAM-EGFR was found to be significant for optimizing detection of the p.T790M mutation. Also, it was noted that each of the mutation detection assay provided complementary clinical value. Mutations in other oncogenes that could be relevant to secondary resistance mechanisms were identified by using NGS, whereas clinically actionable mutations were identified with a higher sensitivity with the OncoBEAM-EGFR assay.